Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion - PubMed (original) (raw)

. 2006 Sep 1;66(12):1311-8.

doi: 10.1002/pros.20464.

Affiliations

• PMID: 16705739
• DOI: 10.1002/pros.20464

Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion

Yi Lu et al. Prostate. 2006.

Abstract

Background: Monocyte chemotactic protein-1 (MCP-1) plays a key role in the recruitment and activation of monocytes during inflammation. Increased MCP-1 serum levels in patients with various cancers were correlated with advanced stage. Here, we evaluated the role of MCP-1 on prostate cancer (CaP) cell proliferation and invasion.

Methods: Expression of MCP-1 in tissue specimens was analyzed by immunohistochemical staining. MCP-1 production was determined by ELISA in conditioned media collected from primary prostate epithelia (PrEC), LNCaP, C4-2B, PC3 cells, and hFOB. Cell proliferation and invasion were assayed by MTS assay and invasion chambers.

Results: All CaP cells, as well as hFOB, produced high amount of MCP-1 compared to PrEC cells. MCP-1 expression levels were associated with advanced pathologic stage. MCP-1 induced proliferation and invasion of CaP cells and this was abolished partially either by CCR2 antagonist or PI3 Kinase inhibitor.

Conclusion: MCP-1 acts as a paracrine and autocrine factor for CaP growth and invasion.

(c) 2006 Wiley-Liss, Inc.

PubMed Disclaimer

Similar articles

• CCR2 expression correlates with prostate cancer progression.
  Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J. Lu Y, et al. J Cell Biochem. 2007 Jun 1;101(3):676-85. doi: 10.1002/jcb.21220. J Cell Biochem. 2007. PMID: 17216598
• Adipocyte-derived monocyte chemotactic protein-1 (MCP-1) promotes prostate cancer progression through the induction of MMP-2 activity.
  Ito Y, Ishiguro H, Kobayashi N, Hasumi H, Watanabe M, Yao M, Uemura H. Ito Y, et al. Prostate. 2015 Jul 1;75(10):1009-19. doi: 10.1002/pros.22972. Epub 2015 Apr 27. Prostate. 2015. PMID: 25917126
• CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
  Lu Y, Wang J, Xu Y, Koch AE, Cai Z, Chen X, Galson DL, Taichman RS, Zhang J. Lu Y, et al. Mol Cancer Res. 2008 Apr;6(4):546-54. doi: 10.1158/1541-7786.MCR-07-0277. Epub 2008 Mar 14. Mol Cancer Res. 2008. PMID: 18344492
• Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.
  Lu Y, Chen Q, Corey E, Xie W, Fan J, Mizokami A, Zhang J. Lu Y, et al. Clin Exp Metastasis. 2009;26(2):161-9. doi: 10.1007/s10585-008-9226-7. Epub 2008 Nov 11. Clin Exp Metastasis. 2009. PMID: 19002595
• Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.
  Zhang J, Lu Y, Pienta KJ. Zhang J, et al. J Natl Cancer Inst. 2010 Apr 21;102(8):522-8. doi: 10.1093/jnci/djq044. Epub 2010 Mar 16. J Natl Cancer Inst. 2010. PMID: 20233997 Free PMC article. Review.

Cited by

• Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models.
  Zollo M, Di Dato V, Spano D, De Martino D, Liguori L, Marino N, Vastolo V, Navas L, Garrone B, Mangano G, Biondi G, Guglielmotti A. Zollo M, et al. Clin Exp Metastasis. 2012 Aug;29(6):585-601. doi: 10.1007/s10585-012-9473-5. Epub 2012 Apr 7. Clin Exp Metastasis. 2012. PMID: 22484917
• CCL2 is critical for immunosuppression to promote cancer metastasis.
  Kudo-Saito C, Shirako H, Ohike M, Tsukamoto N, Kawakami Y. Kudo-Saito C, et al. Clin Exp Metastasis. 2013 Apr;30(4):393-405. doi: 10.1007/s10585-012-9545-6. Epub 2012 Nov 11. Clin Exp Metastasis. 2013. PMID: 23143679
• Elevated Expression Levels of PC3-Secreted Microprotein (PSMP) in Prostate Cancer Associated With Increased Xenograft Growth and Modification of Immune-Related Microenvironment.
  Pei X, Zheng D, She S, Fang Z, Zhang S, Hu H, Xu K, Wang Y. Pei X, et al. Front Oncol. 2019 Aug 28;9:724. doi: 10.3389/fonc.2019.00724. eCollection 2019. Front Oncol. 2019. PMID: 31555577 Free PMC article.
• Anti-Inflammatory Agents for Cancer Therapy.
  Rayburn ER, Ezell SJ, Zhang R. Rayburn ER, et al. Mol Cell Pharmacol. 2009;1(1):29-43. doi: 10.4255/mcpharmacol.09.05. Mol Cell Pharmacol. 2009. PMID: 20333321 Free PMC article.
• Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.
  Yumimoto K, Sugiyama S, Mimori K, Nakayama KI. Yumimoto K, et al. Cancer Sci. 2019 Jul;110(7):2090-2099. doi: 10.1111/cas.14075. Epub 2019 Jun 10. Cancer Sci. 2019. PMID: 31111571 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal